Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study

Lorenzo Gerratana; Yue Ren; Rubina Qamar; et al; Aurora Complex General Surgical Oncology Faculty

doi:10.1200/JCO.2023.41.16_suppl.1059

Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study

Lorenzo Gerratana, Yue Ren, Rubina Qamar, et al, Aurora Complex General Surgical Oncology Faculty

Complex General Surgical Oncology Faculty at Aurora

Advocate Aurora Health

Research output: Contribution to journal › Meeting abstract

Original language	American English
Journal	Journal of Clinical Oncology
DOIs	https://doi.org/10.1200/JCO.2023.41.16_suppl.1059
Status	Published - Jun 1 2023

Keywords

circulating tumor cells
CTC
metastatic breast cancer
hormones

Access to Document

10.1200/JCO.2023.41.16_suppl.1059License: Unspecified

https://libkey.io/libraries/1712/10.1200/JCO.2023.41.16_suppl.1059

Cite this

@article{79a83dbc28354b04ae6b2dd98b1cb2bc,

title = "Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study",

keywords = "circulating tumor cells, CTC, metastatic breast cancer, hormones",

author = "Lorenzo Gerratana and Yue Ren and Rubina Qamar and \{et al\} and \{Complex General Surgical Oncology Faculty\}, Aurora",

note = "Ren Y, Reduzzi C, Regan MM, et al. Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study. Journal of Clinical Oncology. 2023;41(16\_suppl):1059-1059. doi:10.1200/JCO.2023.41.16\_suppl.1059",

year = "2023",

month = jun,

day = "1",

doi = "10.1200/JCO.2023.41.16\_suppl.1059",

language = "American English",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study

AU - Gerratana, Lorenzo

AU - Ren, Yue

AU - Qamar, Rubina

AU - et al, null

AU - Complex General Surgical Oncology Faculty, Aurora

N1 - Ren Y, Reduzzi C, Regan MM, et al. Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study. Journal of Clinical Oncology. 2023;41(16_suppl):1059-1059. doi:10.1200/JCO.2023.41.16_suppl.1059

PY - 2023/6/1

Y1 - 2023/6/1

KW - circulating tumor cells

KW - CTC

KW - metastatic breast cancer

KW - hormones

UR - https://institutionalrepository.aah.org/auroragme/284

UR - https://libkey.io/libraries/1712/10.1200/JCO.2023.41.16_suppl.1059

U2 - 10.1200/JCO.2023.41.16_suppl.1059

DO - 10.1200/JCO.2023.41.16_suppl.1059

M3 - Meeting abstract

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study

Keywords

Access to Document

Other files and links

Cite this